Tamoxifen, a selective estrogen receptor modulator, is commonly used for the treatment and prevention of breast cancer. 1, 2 The clinical response to tamoxifen varies widely among patients, 2 and the identification of determinants of this variability is important, especially in an era of personalized medicine. Tamoxifen undergoes extensive hepatic and gut wall metabolism in humans to several primary and secondary metabolites that exhibit a range of pharmacologic activity. 3, 4 Therefore differences in systemic exposure of one or more of its active metabolites likely contribute to the variable response of tamoxifen observed in patients with breast cancer. 5 Since its first description in 1977, 6 4-hydroxytamoxifen has been considered to be the principal active metabolite of tamoxifen because of its high affinity for estrogen receptors and 30-to 100-fold greater potency than tamoxifen in suppressing estrogen-dependent breast cancer cell proliferation in vitro. 6 -8 However, our group has recently investigated another metabolite of tamoxifen, 4-hydroxy-Ndesmethyltamoxifen (endoxifen) (Fig 1) . Although this metabolite was reported in the 1980s in humans, 9 its pharmacologic relevance remained unknown. Through a series of laboratory and clinical studies, we have demonstrated that (1) endoxifen formation proceeds stepwise by oxidation of tamoxifen with N-desmethyltamoxifen (NDM) as the predominant intermediate (Fig 1) , 3 (2) endoxifen has a potency in vitro that is equivalent to the potency of 4-hydroxytamoxifen and it reaches greater than 6-fold higher plasma concentrations, on average, than 4-hydroxytamoxifen in patients taking tamoxifen, 7, 10 and (3) plasma concentrations in patients receiving tamoxifen are influenced by cytochrome P450 (CYP) 2D6 genetic variants and concomitant intake of known CYP2D6 inhibitor drugs (eg, paroxetine). 7, 10 Evidence that CYP2D6 activity is a determinant of tamoxifen efficacy and adverse effects has been obtained from our recent retrospective analysis in which breast cancer patients who were poor metabolizers of CYP2D6 had a worse clinical outcome (increased recurrence and mortality rates) and fewer adverse effects compared with those who were extensive metabolizers of CYP2D6. 11 It follows that an improved understanding of factors that influence CYP2D6 activity in breast cancer patients and its consequences on endoxifen formation is important to the rational optimization of tamoxifen therapy.
CYP2D6 activity is highly variable in the human population, [12] [13] [14] largely as a result of polymorphisms in the CYP2D6 gene. 15 35 , and * 41) has been reported in subjects with unusually high CYP2D6 catalytic activity. 17, 18 In our pilot clinical study we have established the link between endoxifen plasma concentrations and CYP2D6 status. 7 More recently, we tested the association between tamoxifen metabolism and 4 CYP2D6 null alleles and concomitantly administered CYP2D6 inhibitors in 80 breast cancer patients treated with 20 mg/d tamoxifen. 10 These data indicate that intersubject variability in the endoxifen concentration is accounted for in part by CYP2D6 genotype and by concomitant medications that inhibit CYP2D6 activity. However, we observed a large interpatient variability in the endoxifen concentration even after correcting for CYP2D6 status. This residual variability could result in part from rare CYP2D6 null alleles or variants that are associated with reduced activity and that were not determined in our previous study. To address this issue, we have carried out a thorough investigation of the CYP2D6 genetic polymorphisms in the whole cohort of 158 patients. In addition to the 4 alleles studied previously, 29 additional alleles with different effects on CYP2D6 activity were analyzed by use of the researchbased AmpliChip CYP450 Test (Roche Molecular Systems, Alameda, Calif). In addition, we intended to replicate our initial observation that concomitantly prescribed drugs which are known to be CYP2D6 inhibitors reduce endoxifen plasma concentrations.
METHODS

Patients
Eligible women were recruited into a prospective cohort registry from 3 breast cancer clinics-the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, DC; the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, Ann Arbor, Mich; and the Indiana University Cancer Center, Indianapolis, Ind. Premenopausal and postmenopausal women (aged Ն18 years) with newly diagnosed breast cancer who were starting tamoxifen as standard adjuvant therapy were included in this registry. Patients were enrolled after they had completed all primary surgery, radiation, and adjuvant chemotherapy. They were excluded from the registry if they had started tamoxifen therapy concurrently with either adjuvant chemotherapy or adjuvant radiation therapy (or both) or if they were undergoing other adjuvant endocrine therapies. Other reasons for exclusion included current long-term corticosteroid therapy (previous use during adjuvant chemotherapy was permitted) and use of clonidine, combinations of ergotamine and phenobarbital, or megestrol acetate (INN, megestrol) for hot flash therapy. Patients who were pregnant or lactating were also excluded from the registry. Enrolled patients were allowed to take vitamin E, selective serotonin reuptake inhibitors (SSRIs), or herbal remedies, provided that they had been taking these drugs for at least 4 weeks and intended to continue taking them for at least the first month while participating in the study. Likewise, patients were allowed to begin therapy with the mentioned medications while participating in the study, provided that they were willing to continue the treatment for at least 1 month. The registry protocol was approved by the institutional review boards of all 3 participating sites. All patients provided written informed consent before entry.
Study design
In this report we present data that relate to genetic polymorphisms in CYP2D6 and plasma concentrations of tamoxifen and its metabolites from 158 women who had been entered into the registry. These women were selected for this study because they had completed the necessary physical and laboratory examinations at baseline and 1, 4, 8, and 12 months after the start of tamoxifen therapy (20 mg/d orally in a single dose in the morning) to be included in this analysis. At the mentioned time points, medical histories, including a comprehensive list of current medications, were obtained, and blood samples (5 mL) were drawn in most patients immediately before the following dose of tamoxifen. In some cases blood samples were drawn at random. However, given the long half-life of tamoxifen (5-7 days), 19, 20 we do not expect a large variability in plasma concentrations of tamoxifen or its metabolites at steady state as a result of differences in sampling time. Blood was collected in heparinized tubes, and plasma was separated within 1 hour of blood collection by centrifugation at 2060g. All samples (plasma and whole blood) were transferred to cryogenic vials (Corning, Cambridge, Mass), shipped to the laboratory of the Division of Clinical Pharmacology, Indiana University, on dry ice, and stored at Ϫ80°C pending analysis.
Sample analysis
Analysis of concentrations of tamoxifen and its metabolites in plasma. The plasma concentrations of tamoxifen and its metabolites were determined by use of an HPLC system developed 21 and subsequently modified by our group. 3 This method involves a column-switching and online photocyclization technique in which the eluent, after chromatographic separation, passes through an ICT Beam Boost postcolumn photoreactor supplied with a 5-m reaction coil and a 254-nm ultraviolet lamp (Advanced Separation Technologies, Whippany, NJ), in which the photoreaction converts tamoxifen and its metabolites to highly fluorescent phenanthrene derivatives.
CYP2D6 genotyping. Genomic deoxyribonucleic acid (DNA) was extracted from the leukocyte portion of whole blood by use of a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, Calif) and used for genotyping of CYP2D6 variants. CYP2D6*3, *4, *6, *7, and *8 variant alleles were genotyped by use of a Taqman Allelic Discrimination Assay (Applied Biosystems, Foster City, Calif) according to the manufacturer's in-structions. CYP2D6*10 and *17 were assayed by endonuclease-specific mutation analysis of a 4.7-kilobase pair DNA fragment that contained the CYP2D6 gene. This DNA fragment was amplified from the genomic DNA by use of an expanded long-template polymerase chain reaction and then used as a template to determine specific genetic variants by restriction fragment length polymorphism (RFLP) analysis as described elsewhere. 22, 23 The digested polymerase chain reaction products were then analyzed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Rockville, Md). Some samples were also tested for CYP2D6*3, *4, *6, and *8 variants by use of the RFLP assay described previously. We also assayed for the CYP2D6*41 intronic variant recently described by Raimundo et al. 24 In 
Statistical analysis
The phenotype data, including endoxifen plasma concentrations and endoxifen/NDM and NDM/endoxifen plasma concentration ratios, were analyzed by use of normit plots (or quantile-quantile [Q-Q] plots) to obtain initial information about the distribution of the data. Because the normit plot itself cannot be directly used to decide how many mixture components the distribution contains, we used a mixture normal model approach, 26 -28 which allowed us to select the number of components using the Bayesian information criterion. 29 A unique feature of the mixture model is that it assigns each sample the probability of belonging to each normal distribution.
The comparisons of endoxifen/NDM plasma concentration ratios and endoxifen plasma concentrations between genotype groups and between patients taking CYP2D6 inhibitors and those not taking CYP2D6 inhibitors were performed by use of unpaired t tests. Phenotype expression in each defined genotype group was reported as mean Ϯ SD. The association between CYP2D6 genotype and phenotype groups was evaluated by use of the Mantel-Haenszel chi-square test. The effect of concomitant CYP2D6 inhibitors on endoxifen plasma concentrations in different CYP2D6 genotype groups was analyzed by multiple linear regression. P Ͻ .05 was considered statistically significant.
RESULTS
Demographics
The cohort was composed of 158 patients. The median age was 54 years (range, 30-87 years), and the mean body mass index was 28 kg/m 2 (range, 19-58 kg/m 2 ). Most of the patients were white (91.1%), with a small representation of other ethnic groups as follows: black, 5.7%; Arabic, 1.3%; and Hispanic, 0.6%. Ethnicity information could not be obtained in 2 patients (1.3%).
CYP2D6 genotyping
We performed an exhaustive genetic analysis of the CYP2D6 gene in breast cancer patients treated with tamoxifen. We screened for 33 different alleles, including multiple copies of the gene, gene deletion, and alleles that occur at low frequencies in white persons. In most patients the presence of frequent alleles (eg, CYP2D6*3, *4, *6, *7, *8, *10, and *41) was confirmed by 2 or 3 different genotyping methods (ie, RFLP, Taqman Allelic Discrimination Assay, and AmpliChip CYP450 Test). The no-call rate for the AmpliChip CYP450 Test was 0.7%. The discordance between our assays and the AmpliChip CYP450 Test was less than 2% (2/129). In the case of the 2 discordant samples, we decided to include the results obtained by the AmpliChip CYP450 Test.
The frequencies of individual CYP2D6 genotypes are presented in Table I . Null alleles (CYP2D6*3, *4, *5, and *6), dysfunctional alleles (CYP2D6*9, *10, *17, *29, and *41), and functional alleles (CYP2D6*1, *2, and *35) were designated as poor metabolizer (PM), intermediate metabolizer (IM), and extensive metabolizer (EM) alleles, respectively. 15 Multiple copies of any functional allele were designated as ultrarapid metabolizer (UM). 15 As expected, the most frequent alleles were *1 (0.453), *4 (0.161), and *2 (0.13). CYP2D6*4 was the most common null allele and the only allele present in PM/PM genotype patients. The frequencies of other null alleles were 0.022 (*5), 0.013 (*3), and 0.003 (*6). The IM genotype groups (ie, IM/PM and IM/IM) represented 7.6%, rising to 34.2% if EM/PMs were included. CYP2D6*41 was the most frequent dysfunctional allele (0.089), followed by CYP2D6*10 (0.035) and *9 (0.009). Of the patients, 38% had an EM/EM genotype, most of whom (55%) were homozygotes for CYP2D6*1. The remaining 45% were different combinations of CYP2D6*1, *2, and *35. The UM/EM group represented 4.4% of the patients and was primarily composed of multiple copies of the wild-type allele (CYP2D6*1xn). With regard to ethnicity, the black patients carried the CYP2D6*1/*1 (n ϭ 5), *1/*29 (n ϭ1), *1/*5 (n ϭ1), *17/*41 (n ϭ1), or *10/*4 (n ϭ1) genotype. The only Hispanic patient in our study, the 2 Arabic patients, and the 2 patients whose ethnicity was unknown had the CYP2D6*1/*4, *1/*1 and *1/*10, and *1/*4 and *10/*35 genotypes, respectively. All of the other genotypes were found in white patients. In our study we did not find any individual carrying the low-frequency alleles (CYP2D6* 
Plasma concentrations of tamoxifen and its metabolites
Our previous studies have indicated that steady-state plasma concentrations of tamoxifen and its metabolites are achieved in 4 months. 10 The plasma concentrations at 4, 8, and 12 months were measured in selected patients and found to be comparable. Therefore we present the data collected after 4 months of treatment with tamoxifen. At the fourth month, 46 patients (29%) were receiving CYP2D6 inhibitors concomitantly, 33 of whom were taking SSRIs. We were not able to obtain information about concomitant medications in 18 patients. These 18 patients were excluded from the analysis of the effect of CYP2D6 inhibitors on tamoxifen pharmacokinetics.
Mean plasma concentrations (ϮSD) of tamoxifen, NDM, 4-hydroxytamoxifen, and endoxifen in the whole cohort (N ϭ 158) were 334.5 Ϯ 147.9 nmol/L, 695.2 Ϯ 353.8 nmol/L, 7.4 Ϯ 3.7 nmol/L, and 61.2 Ϯ 40.6 nmol/L, respectively. There was no significant difference in mean plasma concentrations of tamoxifen, NDM, and 4-hydroxytamoxifen between patients receiving concomitant CYP2D6 inhibitors and those not receiving concomitant CYP2D6 inhibitors (332.2 Ϯ 151.1 nmol/L versus 337.6 Ϯ 156.7 nmol/L [P ϭ .85], 686.9 Ϯ 328.2 nmol/L versus 638.9 Ϯ 326.7 nmol/L [P ϭ .42], and 7.02 Ϯ 3.6 nmol/L versus 7.8 Ϯ 3.9 nmol/L [P ϭ .29], respectively). However, the mean endoxifen plasma concentration was significantly lower in patients taking CYP2D6 inhibitors than in those not taking any concomitant CYP2D6 inhibitors (39.6 Ϯ 28.4 nmol/L versus 71.5 Ϯ 41.2 nmol/L, P Ͻ .01). These findings reflect the importance of the CYP2D6 enzyme in the formation of endoxifen.
It has been shown that the plasma concentration of CYP2D6 substrates follows a multimodal distribution. 13 To evaluate this phenomenon in our study, we used the normit plot (or Q-Q plot) and a mixture model approach, as described in the "Statistical Analysis" section. When all patients were included in the analysis, the endoxifen plasma concentration and NDM/endoxifen and endoxifen/NDM plasma concentration ratios showed curved normit plots (Fig 2, A) , indicating that the distribution of all 3 parameters was not homogeneous within the study population but, rather, was composed of a mixture of normal distributions. When these variables were fitted into the mixture normal model, the endoxifen plasma concentration contained 2 components and both NDM/endoxifen and endoxifen/NDM plasma concentration ratios contained 4 components (Fig 2, B) . According to the mixture model analysis, each patient was assigned a probability of belonging to each group. For example, if a patient's endoxifen plasma concentration was below the cut point of 52.2 nmol/L, it was more probable that this patient belonged to the first normal component; otherwise, it was more likely that the patient was part of the second component. On the basis of these probabilities, the patients were clustered into different groups or classes (Fig 2,  C) . Accordingly, the endoxifen plasma concentration identified 2 distinct subgroups of patients within the population, whereas NDM/endoxifen and endoxifen/ NDM plasma concentration ratios identified 4, suggesting that the ratios were more efficient in discriminating phenotypic subpopulations. The same pattern of distribution of the endoxifen plasma concentration and NDM/endoxifen and endoxifen/NDM plasma concentration ratios was observed when patients who were taking CYP2D6 inhibitors along with tamoxifen were excluded from the analysis, further supporting the existence of the mentioned subgroups within our study population (Fig 3) . NDM/endoxifen and endoxifen/ NDM plasma concentration ratios provided the same information. For the sake of space and clarity, we decided to use the endoxifen/NDM plasma concentration ratio alone in subsequent analyses.
Associations of CYP2D6 genotypes with endoxifen plasma concentration and with endoxifen/NDM concentration ratio
The associations of the endoxifen/NDM plasma concentration ratio and the plasma concentration of endoxifen with CYP2D6 genotypes are shown in Fig 4, A and B, respectively. Three distinct genotype groups could be identified in the distribution of endoxifen/NDM plasma concentration ratio as follows: 1 group with low ratios (mean, 0.04 Ϯ 0.02) represented by patients lacking any fully functional CYP2D6 allele (triangles in Fig 4, A) , 1 group with intermediate ratios (mean, 0.08 Ϯ 0.045) composed of patients carrying only 1 fully functional CYP2D6 allele (circles in Fig 4, A) , and a third group with higher ratios (mean, 0.15 Ϯ 0.09) comprising patients with 2 or more copies of any functional or dysfunctional CYP2D6 allele (diamonds in Fig   Fig 3 . 
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Genotypes represented by only 1 patient were excluded from the group comparison (squares in Fig 4,  A) . The endoxifen/NDM plasma concentration ratio was significantly different between groups (P Ͻ .001).
Although the endoxifen plasma concentration was also associated with CYP2D6 genotypes, this association was less marked compared with that of the ratio (Fig 4,  B) . Therefore we chose the ratio as a more sensitive marker of CYP2D6. When the patients taking CYP2D6 inhibitors were excluded from the analysis, the separation of genotype groups by endoxifen/NDM plasma concentration ratio became more evident (Fig 5, A) . Although the same applies to the endoxifen plasma concentration, its high variability reduced its ability to discriminate separate genotypic groups (Fig 5, B) .
After identifying distinct phenotype and genotype subgroups within the study population, we analyzed how these groups related to each other. We calculated the relative representation of the different CYP2D6 genotypes in each phenotype group or class defined by the mixture normal model (Table II) . Genotypes represented by only 1 patient were not considered in this analysis. The relative frequencies of the CYP2D6 genotypes followed an opposite trend to the functionality of the CYP2D6 alleles in the first phenotype group; the contrary occurred in the last phenotype group. That is, genotypes with more functional CYP2D6 alleles were less represented in the first phenotype group than in the last one, and vice versa. This phenomenon was observable in both the endoxifen plasma concentration and endoxifen/NDM plasma concentration ratio. It is remarkable that all of the patients with the PM/PM genotype belonged to the first group of endoxifen plasma concentration. Similarly, all of the patients lacking fully functional CYP2D6 alleles were present in the first 2 endoxifen/NDM plasma concentration ratio phenotype groups, and none of the patients carrying more than 2 fully functional CYP2D6 alleles belonged to the first endoxifen/NDM plasma concentration ratio group. These differences in the distribution of CYP2D6 genotype groups within each phenotype group were statistically significant (P Ͻ .0001).
Effect of CYP2D6 inhibitors on plasma concentrations of endoxifen
We examined the effect of coprescribed CYP2D6 inhibitors on endoxifen plasma concentrations. There was a significant decrease in mean endoxifen plasma concentration in patients taking CYP2D6 inhibitors (n ϭ 46) in comparison with those not taking any concomitant CYP2D6 inhibitors (n ϭ 94) within the whole cohort of 158 patients (39.6 Ϯ 28.4 nmol/L versus 71.5 Ϯ 41.2 nmol/L, P Ͻ .01). We divided the CYP2D6 inhibitors into 2 groups according to their inhibitory potency. 30 Potent inhibitors were represented by the SSRIs paroxetine and fluoxetine (n ϭ 19). Weak inhibitors consisted of sertraline and citalopram among the SSRIs (n ϭ 14), as well as other drugs such as celecoxib, diphenydramine, and chlorpheniramine (n ϭ 13). Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, does not affect CYP2D6 activity and thus was considered separately (n ϭ 6). We found a more pronounced decrease in mean endoxifen plasma concentrations with potent CYP2D6 inhibitors than with weak CYP2D6 inhibitors (24.6 Ϯ 16.6 nmol/L versus 50.1 Ϯ 30.4 nmol/L, P Ͻ .01). Concomitant use of venlafaxine did not show any significant effect on mean endoxifen plasma concentration (71.7 Ϯ 41.3 nmol/L versus 80.8 Ϯ 39.3 nmol/L, P ϭ .60). To separate the effect of the inhibition from that of the CYP2D6 genotype, we analyzed the effect of CYP2D6 inhibitors in those patients with the EM genotype (EM/EM) (Fig 6) . As expected, the mean endoxifen plasma concentration in CYP2D6 EM patients who were not taking CYP2D6 inhibitors (84.1 Ϯ 39.4 nmol/L) was similar to that in patients receiving venlafaxine (93.6 Ϯ 38.6 nmol/L) (P ϭ .72). There was a trend toward a decrease in mean endoxifen plasma concentration in patients taking weak CYP2D6 inhibitors (63.9 Ϯ 36.9 nmol/L) compared with that in patients not receiving CYP2D6 inhibitors, but this difference did not reach statistical significance (P ϭ .15). The concomitant use of potent CYP2D6 inhibitors resulted in a marked reduction in mean plasma endoxifen concentration (23.5 Ϯ 9.5 nmol/L) in comparison with the concentrations achieved when none of these drugs was coadministered (P Ͻ .0001). This low mean endoxifen plasma concentration brought about by the potent inhibitors of CYP2D6 was comparable to that in patients with the CYP2D6 PM genotype status (19.4 Ϯ 6.1 nmol/L, P ϭ .43), suggesting a "phenocopy."
We next evaluated the effect of CYP2D6 inhibitors on the endoxifen plasma concentration in different CYP2D6 genotype groups (Fig 7) . The same trend described in EM/EMs was observed in other CYP2D6 genotypes (P ϭ .003). Weak inhibitors slightly reduced the endoxifen plasma concentration, whereas potent inhibitors consistently caused a significant decrease. This effect was not so clear in the CYP2D6 EM/*10 genotype, probably because of the small number of patients included in this category. It is worth noting that the UM/EM group is the only genotype group that appeared not to be converted into a PM status by CYP2D6 potent inhibitors. It is also remarkable that CYP2D6 Genotype 
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DISCUSSION
This study provides the first comprehensive analysis of the association between concentrations of the active metabolites of tamoxifen and CYP2D6 variants, as well as exposure to inhibitors of CYP2D6, providing important information that may be pragmatically applied to the individualization of tamoxifen therapy. Although the link between CYP2D6 status and tamoxifen metabolism was established in our previous studies, the current work incorporates approaches such as normit analysis and mixture normal model distribution to quantitatively determine the association of CYP2D6 genetics and drug interactions with tamoxifen metabolism in a larger population of patients.
In this study the frequency of the PM/PM genotype was slightly lower (4.4%) than expected (5%-10%) in a white population, 14 whereas the frequencies of the intermediate genotypes (ie, IM/PM and IM/IM) and the IM allele *41 were similar to those in previous re- ports. 24 However, CYP2D6*10 was more common in our sample (0.035) than in other comparable populations (0.015-0.018). 14, 24 Another difference between our study patients and other white groups was the higher representation of the UM/EM genotype (4.4% versus 1.2%-1.3%), 14 which was mostly explained by multiple copies of the *1 allele. These discrepancies in the CYP2D6 allelic frequency may be the result of minor differences between different white populations and the small contribution of other ethnic groups to our cohort.
We examined the genotype-to-phenotype association by a combination of the mixture normal model analysis and stratification of genotype groups. The distribution of the endoxifen plasma concentration and the endoxifen/NDM plasma ratio showed 2 and 4 phenotype groups, respectively, suggesting that the ratio is a better index measure of CYP2D6 activity. On the other hand, the genotype stratification identified 3 distinct genotype groups in relation to both the endoxifen plasma concentration and its ratio to NDM. These data indicate that CYP2D6 genotype can explain part of the variability in the endoxifen plasma concentration and the endoxifen/NDM plasma ratio. Furthermore, when we evaluated the relative frequencies of the CYP2D6 genotypes within each endoxifen/NDM plasma concentration ratio or endoxifen plasma concentration phenotype group (Table II) , CYP2D6 genotype appeared to be a good tool by which to estimate the phenotype. The pattern of the distribution of genotypes within the phenotype groups suggests that CYP2D6 genotype may allow estimation of what the endoxifen concentration would be in breast cancer patients being treated with tamoxifen in clinical settings in whom CYP2D6 genotype is known. Together, our data suggest that the iterative approaches and models used in this report appear to be valuable tools in the study of CYP2D6 and other complex genotype-phenotype relationships.
We also assessed the effect of the concomitant prescription of inhibitors of CYP2D6 on tamoxifen metabolism, which may have important clinical implications. We focused on antidepressants in this study because of their frequent use with tamoxifen for the treatment of hot flashes or mood disorders. SSRIs/ serotonin-norepinephrine reuptake inhibitors are the most promising nonhormonal treatment for hot flashes in women with breast cancer. Preliminary data support the use of citalopram and sertraline for the treatment of this frequent menopausal symptom 31, 32 ; paroxetine, fluoxetine, and venlafaxine have been reported to decrease hot flash scores by 64.6%, 50%, and 61%, respectively. [33] [34] [35] In our study the simultaneous use of venlafaxine and tamoxifen did not appear to affect the endoxifen plasma concentration, whereas weak CYP2D6 inhibitors (eg, citalopram and sertraline) slightly decreased mean plasma concentrations of en- doxifen. In accordance with our previous reports, potent CYP2D6 inhibitors (eg, paroxetine and fluoxetine) showed the largest reduction in the concentration of endoxifen, converting CYP2D6 EMs into a PM status (phenocopy). Although we do not have enough statistical power to compare UM/EMs and the other CYP2D6 genotypes, the concomitant use of potent CYP2D6 inhibitors and tamoxifen in UM/EM patients seems to produce a less pronounced decrease in mean endoxifen plasma concentration. Because paroxetine and fluoxetine are substrates of this enzyme, it is possible that the relatively high concentration of the enzyme that results from multiple copies may rapidly metabolize these inhibitors and result in an inadequate concentration of the inhibitor at the enzyme site to adequately inhibit the conversion of NDM to endoxifen. It is of note that none of the patients with the *41/PM or PM/PM genotype were receiving concomitant CYP2D6 inhibitors. The reason for this observation is unclear, but it is consistent with a previous report that patients who are PMs of CYP2D6 had a low incidence of severe hot flashes. 11 Because most of the potent inhibitors are CYP2D6 substrates, the possibility that PM patients may not tolerate these drugs or PMs may not require prescription of these SSRIs cannot be ruled out.
Available in vitro and clinical evidence points toward an important role for endoxifen in the clinical effect of tamoxifen. The data from this study together with our previous reports indicate a strong association between endoxifen concentrations, CYP2D6 genotypes, and inhibitors of the enzyme. In a recent retrospective analysis of a randomized, blinded, prospective clinical study, we found that breast cancer patients who were PMs of CYP2D6 benefit less from tamoxifen therapy compared with EMs. 11 However, some variability in the endoxifen plasma concentration remains unexplained even after correction by CYP2D6 genotype and medication history. Although the contribution of CYP3A to the endoxifen concentration appears to be very small, this route may become apparent when CYP2D6 activity is diminished. In addition, endoxifen plasma concentrations are likely to be dependent on its formation and clearance by phase II enzymes (eg, sulfation and probably glucuronidation). It follows that CYP2D6 and other factors should be considered for a full understanding of the intersubject variability of endoxifen concentrations.
In conclusion, if the preliminary associations between clinical outcomes of tamoxifen and CYP2D6 genotype are confirmed, 11 analyses of endoxifen and CYP2D6 may be useful to optimize tamoxifen treatment. On the other hand, the endoxifen/NDM plasma ratio may serve as a marker of CYP2D6 activity during tamoxifen treatment. Although some SSRIs greatly interfere with tamoxifen metabolism, citalopram, sertraline, and venlafaxine appear to have less impact on the endoxifen concentration and thus are probably better therapeutic alternatives in breast cancer patients undergoing tamoxifen therapy who require the use of antidepressants. 
